Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06791057 · ClinicalTrials.gov registry record · NA
Multi-site Trial of a Brief Behavioral Intervention for Dyspnea in Patients With Advanced Lung Cancer
A NA study, sponsored by Massachusetts General Hospital.
- Not yet
- Registry status
- NA
- Development phase
- 420
- Enrollment target
NCT06791057: Clinical Trial NA study, sponsored by Massachusetts General Hospital.
NCT06791057 is a NA study that has not yet begun recruiting, run by Massachusetts General Hospital. The registered enrollment target is 420 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06791057, a NA study, has not yet begun recruiting, sponsored by Massachusetts General Hospital.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 420 participants
- Enrollment target
Study Summary
Dyspnea, or breathlessness, is one of the most common and distressing symptoms experienced by patients with advanced lung cancer. The purpose of this multi-site trial is to test the effectiveness of a dyspnea intervention (called BREEZE+) that includes three brief nurse-delivered sessions and access to a digital health app that teaches and reinforces patients' use of skills for managing and coping with this highly debilitating symptom. This study will lay the groundwork for a follow-up pragmatic implementation trial integrating BREEZE+ into usual oncology care for patients with advanced lung cancer experiencing dyspnea.
Primary Outcome
To compare patient-reported dyspnea between study groups at 8 weeks using the Modified Medical Research Council Dyspnea Scale, which is a one-item self-report scale to evaluate the degree of a patient's dyspnea (score range: 0-4), with a higher score indicating worse dyspnea.
Interventions
- BEHAVIORAL Enhanced Usual Care
- BEHAVIORAL Dyspnea Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 2026-09-01 |
| Est. Completion | 2030-03-31 |
| Phase | NA |
What is known before NCT06791057 opens enrollment
NCT06791057 is an interventional study that assigns participants to a tested intervention. The registered 420 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 2 interventions - of which Enhanced Usual Care is the first listed.
NCT06791057 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06791057 about?
NCT06791057 is a clinical study titled "Multi-site Trial of a Brief Behavioral Intervention for Dyspnea in Patients With Advanced Lung Cancer". Dyspnea, or breathlessness, is one of the most common and distressing symptoms experienced by patients with advanced lung cancer. The purpose of this multi-site trial is to test the effectiveness of a dyspnea intervention (called BREEZE+) that includes three brief nurse-delivered sessions and access...
What is the current status of trial NCT06791057?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 420 participants. The study started on 2026-09-01. Estimated completion is 2030-03-31.
What interventions are being tested in trial NCT06791057?
The interventions under investigation include: Enhanced Usual Care (BEHAVIORAL), Dyspnea Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT06791057?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06791057's enrollment target sits among peer trials
420 239th of 2000 higher than 1,761 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01790152 · 420 participants
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- NCT02701244 · 420 participants
A Registry Study of Breast Microseed Treatment
- NCT02966665 · 420 participants · Phase 1
: Vascular Function in Health and Disease
- NCT04149743 · 420 participants · NA
HEMOTAG® Assessment for Short-term Outcomes of Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI